Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -7.60% is 68% above its 5-year average of -24.04%, near the high end of its 5-year range (-51.19%–-7.60%).
64.20% above its 12-month average of -21.23%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.04%.
RETURN ON ASSETS (ROA)
-7.60%
RETURN ON ASSETS (ROA) AVG TTM
-21.23%
RETURN ON ASSETS (ROA) AVG 3Y
-30.23%
RETURN ON ASSETS (ROA) AVG 5Y
-24.04%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+64.20%
CURRENT VS 3Y AVG
+74.86%
CURRENT VS 5Y AVG
+68.38%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+76.43%
vs the sector median at left
Tarsus Pharmaceuticals, Inc.
Market Cap
$3.19B
Return on Assets (ROA)
-7.60%
TTM Avg
-21.23%
3Y Avg
-30.23%
5Y Avg
-24.04%
Market Cap
$3.12B
Return on Assets (ROA)
-57.49%
TTM Avg
-99.67%
3Y Avg
-60.13%
5Y Avg
-103.92%
Market Cap
$3.30B
Return on Assets (ROA)
20.83%
TTM Avg
2.76%
3Y Avg
-12.34%
5Y Avg
-9.97%
Market Cap
$3.31B
Return on Assets (ROA)
-102.47%
TTM Avg
-31.18%
3Y Avg
-31.63%
5Y Avg
-28.00%
Market Cap
$3.06B
Return on Assets (ROA)
-44.17%
TTM Avg
-37.77%
3Y Avg
-27.61%
5Y Avg
-21.12%
Market Cap
$3.03B
Return on Assets (ROA)
-11.64%
TTM Avg
-24.55%
3Y Avg
-30.16%
5Y Avg
-27.23%
Market Cap
$3.36B
Return on Assets (ROA)
-180.51%
TTM Avg
-129.75%
3Y Avg
-129.75%
5Y Avg
-129.75%
Market Cap
$3.38B
Return on Assets (ROA)
21.83%
TTM Avg
22.04%
3Y Avg
-0.21%
5Y Avg
-10.13%
Market Cap
$2.99B
Return on Assets (ROA)
5.84%
TTM Avg
-21.93%
3Y Avg
-47.49%
5Y Avg
-47.67%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | $3.19B | -7.60% | -21.23% | -30.23% | -24.04% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | -57.49% | -99.67% | -60.13% | -103.92% |
| CareDx, Inc (CDNA)vs › | $3.30B | 20.83% | 2.76% | -12.34% | -9.97% |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | -102.47% | -31.18% | -31.63% | -28.00% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | -44.17% | -37.77% | -27.61% | -21.12% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | -11.64% | -24.55% | -30.16% | -27.23% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | -180.51% | -129.75% | -129.75% | -129.75% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 21.83% | 22.04% | -0.21% | -10.13% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 5.84% | -21.93% | -47.49% | -47.67% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -69.27% | -58.09% | -65.66% | -83.41% |
ROA
-7.6%
ROE
-13.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -11.81% |
| 2024-12-31 | -30.65% |
| 2023-12-31 | -51.19% |
| 2022-12-31 | -27.25% |
| 2021-12-31 | -7.73% |
| 2020-12-31 | -15.59% |
| 2019-12-31 | -8.01% |
| 2018-12-31 | -55.21% |
